جميع الدراسات
التوظيفالمرحلة 1، المرحلة 2تدخلي

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

This research study is looking into a new medicine, pirtobrutinib, for adults with Immune Thrombocytopenia (ITP). ITP is a condition where your immune system mistakenly attacks and destroys platelets, which are tiny blood cells that help your blood clot. The study has two main parts. The first part will check how well people tolerate pirtobrutinib and look for any unwanted side effects. The second part will compare different doses of pirtobrutinib against a dummy pill (placebo) to see how effective it is in increasing platelet counts and if it's safe. Taking part involves taking the study medicine by mouth and having regular blood tests.

نظرة سريعة

الحالة
التوظيف
المرحلة
المرحلة 1، المرحلة 2
الراعي
شركة إيلي ليلي وشركاه
الهدف من التسجيل
68
ابدأ
30 يوليو 2025
التاريخ المتوقع للانتهاء
01 Feb 2029

ما هو موضوع هذه الدراسة؟

This study is about a new medicine called pirtobrutinib for adults who have a condition called Immune Thrombocytopenia, or ITP. ITP happens when your body's defence system, called the immune system, gets confused and starts attacking your own platelets. Platelets are really important because they help your blood clot and stop bleeding. If you have ITP, your platelet count can be very low, which increases your risk of bruising and bleeding.

The main goal of this study is to find out if pirtobrutinib is a safe and effective treatment for ITP. The study will happen in two stages. First, we need to understand if the medicine is well-tolerated and what kind of side effects it might have. This helps us ensure patient safety. After that, we'll look more closely at whether different amounts (doses) of pirtobrutinib can help increase platelet counts compared to a 'dummy' pill that contains no medicine (a placebo).

If you take part, you'll be given the study medicine, pirtobrutinib, as a tablet to swallow. The researchers will also take blood samples regularly. These blood tests help them understand how much of the medicine gets into your body and how long it stays there. The study will last for different periods depending on which part you are in, but it could be up to about 16 weeks for the first stage or up to 28 weeks for the second stage, not including the initial checks to see if you can join.

النقاط الرئيسية

  • This study is testing a new medicine, pirtobrutinib, for adults with ITP.
  • It aims to check the safety and effectiveness of the medicine.
  • Participants will take the medicine as a tablet and have regular blood tests.
  • The study has two parts: one to find the right dose, and another to compare it with a dummy pill.
  • Taking part means frequent clinic visits and medical supervision.
  • يمكنك التوقف عن المشاركة في أي وقت.

من قد يكون مؤهلاً؟

To be able to join this study, you would need to be an adult (18 years or older) with a specific type of ITP called 'primary ITP'. This means your low platelet count isn't caused by another known illness. You should also have shown some improvement in your platelet count with at least one previous ITP treatment, even if that treatment no longer works for you now. Importantly, your ITP should have returned or not responded well to treatments, and your platelet count generally needs to be quite low (under 30,000) on a couple of recent occasions.

There are also some reasons why you might not be able to join. For example, if you've had a blood clot in the past year, or if you recently needed a blood transfusion. People with certain severe heart conditions, a history of blood cancers, or certain types of hepatitis (like Hepatitis B or C) would also not be able to take part. The study team will check your overall health, including your liver and kidney function, to make sure it's safe for you to participate.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. هل عمرك 18 سنة أو أكثر؟
  2. Have you been diagnosed with primary ITP (ITP not caused by another disease)?
  3. Have you tried at least one ITP treatment before, and it helped at some point?
  4. Is your ITP not responding well to current treatments or has it returned?
  5. Are your platelet counts generally below 30,000?
  6. Do you have suitable liver, kidney, and blood cell function (as determined by tests)?
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you decide to take part in this study, you will be taking the study medicine, pirtobrutinib, as a tablet by mouth. You will have regular visits to the clinic for medical check-ups, which will include physical exams and several blood tests. These blood tests help the study team monitor your platelet counts, check for any side effects, and see how your body handles the medicine. For women who can get pregnant, there will be rules about using contraception during the study. The total time you would be involved in the study could be up to around 16 weeks for the first part or up to 28 weeks for the second part, plus an initial assessment period.

المخاطر والفوائد المحتملة

Taking part in a clinical trial may offer potential benefits, such as access to a new treatment before it's widely available, and you would receive very close medical attention from the study team. However, there are also potential risks, including side effects from the study medicine, which the researchers will carefully monitor. The study will also involve regular clinic visits and blood tests, which can be time-consuming. You are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

المواقع (43)

  • مركز نوريس الشامل للسرطان بجامعة جنوب كاليفورنيا
    الرمز البريدي المؤكد
    لوس أنجلوس، الولايات المتحدة· التوظيف
  • جامعة ستانفورد
    الرمز البريدي المؤكد
    بالو ألتو، الولايات المتحدة· التوظيف
  • مستشفى جامعة ميدستار جورجتاون
    الرمز البريدي المؤكد
    واشنطن العاصمة، الولايات المتحدة· التوظيف
  • University of Miami Hospital and Clinics Sylvester Comprehensive Cancer Center
    الرمز البريدي المؤكد
    ميامي، الولايات المتحدة· لم يبدأ التوظيف بعد
  • Bleeding and Clotting Disorders Institute
    الرمز البريدي المؤكد
    بيوريا، الولايات المتحدة· لم يبدأ التوظيف بعد
  • مؤسسة عيادة أوشنر
    الرمز البريدي المؤكد
    نيو أورلينز، الولايات المتحدة· التوظيف
  • عيادة مايو
    الرمز البريدي المؤكد
    روتشستر، الولايات المتحدة· التوظيف
  • Texas Oncology - Central South
    الرمز البريدي المؤكد
    أوستن، الولايات المتحدة· التوظيف
  • مركز إم دي أندرسون للسرطان
    الرمز البريدي المؤكد
    هيوستن، الولايات المتحدة· التوظيف
  • Texas Oncology Gulf Coast
    الرمز البريدي المؤكد
    The Woodlands, United States· التوظيف
  • Nanfang Hospital of Southern Medical University
    الرمز البريدي المؤكد
    قوانغتشو، الصين· التوظيف
  • Qilu Hospital of Shandong University
    الرمز البريدي المؤكد
    Jinan, China· التوظيف

أسئلة شائعة

What is ITP?

ITP stands for Immune Thrombocytopenia. It's a condition where your body's immune system accidentally attacks and destroys your own platelets, which are blood cells that help stop bleeding.

What is pirtobrutinib?

Pirtobrutinib is the new medicine being tested in this study. It's designed to help manage ITP.

What is a 'dummy pill' (placebo)?

A dummy pill, or placebo, looks just like the real medicine but contains no active drug. It helps researchers compare the effects of the actual medicine fairly.

كم ستستغرق الدراسة إذا انضممت؟

The study could last up to about 16 weeks for the first part or up to 28 weeks for the second part, depending on which stage you are in, plus an initial screening period.

هل يمكنني التوقف عن المشاركة في الدراسة إذا غيرت رأيي؟

Yes, you can leave the study at any time, for any reason. Your decision will not affect your medical care.

كيفية معرفة المزيد

أسئلة التجارب أو أسئلة المشاركة: 1-877-CTLILLY (1-877-285-4559) أو

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

هل أنت مهتم بالمشاركة؟

سجل اهتمامك

شارك تفاصيلك وفريق البحث لـ "A Study of Pirtobrutinib in Participants With Immune Thrombo… "سيتواصل معك إذا كنت مؤهلاً. تحدث دائمًا إلى طبيبك قبل الموافقة على المشاركة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.